Vimarsana
Biggest News Aggregation in the World

Corroborates Hypothesized Ability News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Corroborates Hypothesized Ability. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Corroborates Hypothesized Ability Today - Breaking & Trending Today

EQS-News: Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders - Vimarsana News

EQS-News: Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

Published: May 4, 2023

Issuer: Immunic, Inc. / Key word(s): Study results Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders 04.05.2023 / 12:30 CET/CEST The issuer is solely responsib...

Source: boersennews.de
Related Topics:
United StatesNew ZealandJessica BreuEdna KaplanDaniel VittPaula SchwartzAndreas MuehlerGut HealthExchange CommissionDistribution ServicesImmunic IncRx Communications GroupReports Positive Results From PhaseClinical TrialCeliac DiseaseProviding Clinical Proof Of ConceptNew Therapeutic ApproachGastrointestinal DisordersPositive Effects Demonstrated Over PlaceboFour Key DimensionsCeliac Disease PathophysiologyGut ArchitecturePatient SymptomsBiomarker ResponseNutrient Absorption
Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders - Vimarsana News

Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

Published: May 4, 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

Source: prnewswire.com
Related Topics:
United StatesNew ZealandDaniel VittEdna KaplanJessica BreuPaula SchwartzAndreas MuehlerGut HealthImmunic IncRx Communications GroupExchange CommissionPositive EffectsDemonstrated OverFour Key DimensionsCeliac Disease PathophysiologyGut ArchitecturePatient SymptomsBiomarker ResponseNutrient AbsorptionCorroborates Hypothesized AbilityRenew Gut WallRestore Gut HealthTolerability Issues DetectedConference CallHeld Today